Factors affecting long-term outcomes after postchemotherapy surgery in patients with nonseminomatous germ cell tumors of the mediastinum. Epidermal growth factor receptor (EGFR) targeted therapy in ...
A phase I/II trial of intrarterial infusion of CDDP, 5-FU and gemcitabine in combination with intravenous epirubicin in unresectable pancreatic cancer No significant financial relationships to ...
(HealthDay News) — Chemotherapy at the start of androgen-deprivation therapy (ADT) can extend the lives of men with metastatic, hormone-sensitive prostate cancer, according to research published ...
A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, "Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)." Lung cancer is the ...
AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals (“Modra”) today announced positive data from its Phase IIb trial evaluating its boosted oral taxane therapeutic, ModraDoc006/r, in patients with ...
AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US for the treatment of adult ...
Research by a Washington State University-led team of scientists has identified a receptor protein, CHRM1, as a key player in prostate cancer (PC) cells’ resistance to docetaxel (DTX), a chemotherapy ...
Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- Treatment with single-agent sacituzumab govitecan ...
The second bellwether trial against Sanofi-Aventis over its prescription chemotherapy drug Taxotere began today. The trial in New Orleans is one of nearly 12,500 lawsuits coordinated in multidistrict ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Positive results from the pivotal TROPION-Lung01 phase 3 trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback